Chronic infection with the environmental bacterium Pseudomonas aeruginosa is associated with greater morbidity and mortality for people with cystic fibrosis. Strict infection control measures including segregation appear to reduce but not eliminate the risk of initial acquisition of the organism. There is now good evidence from randomized controlled trials that early eradication regimens consisting of anti-pseudomonal antibiotics are effective in clearing P. aeruginosa and delaying the development of chronic infection in the majority of subjects. These regimens are safe and cost-effective. Ensuring that such regimens are widely adopted is therefore of considerable importance to improving outcomes for people with cystic fibrosis. The most effective antibiotic regimen, and the effects of new nebulizer technologies and methods to improve concordance remain to be determined. Chronic Respiratory Disease 2009; 6: 99-107
Introduction
Cystic fibrosis (CF), the commonest life-shortening genetic condition in the Caucasian population, is an autosomal recessive condition caused by mutations of a gene on chromosome 7 encoding the CF conductance regulator protein. 1 Reduced or absent function of this protein results in an impaired ability to clear mucous from the respiratory tract, along with other features including exocrine pancreatic insufficiency (in approximately 90% of cases) and male infertility. 2 When CF was first described by Dorothy Anderson in 1938, the prognosis was extremely poor, with the majority of identified cases dying in early childhood. 3 Over the past 70 years, the outlook has improved considerably, with current life expectancy believed to be approximately 38 years on average. 4 However, even with modern therapies, it is clear that chronic pulmonary infection, predominantly with the gram-negative environmental organism Pseudomonas aeruginosa, is associated with worse outcome. [5] [6] [7] In CF subjects, P. aeruginosa infection is associated with a lower forced expiratory volume in 1 s (FEV 1 ) in childhood [8] [9] [10] [11] ; a faster decline in FEV 1 in childhood 6, 7, [11] [12] [13] ; and reduced adult survival. 5, 14, 15 In the majority of CF subjects, chronic P. aeruginosa infection is preceded by a period of varying duration during which growth of the organism is intermittent (for definitions see Table 1 ). 10, [16] [17] [18] [19] During this time, the use of antibiotic regimens targeted against P. aeruginosa can eradicate the organism and thus delay or prevent the development of chronic infection (see Figure 1 ). 17, 20 Once chronic P. aeruginosa pulmonary infection is established, eradication of the organism appears impossible using current therapies. 17, 21 Thus, strategies to eradicate P. aeruginosa in the early stages of infection, in conjunction with measures to reduce the risks of initial acquisition, are of paramount importance to delay chronic infection and thus improve long-term outcomes for subjects with CF. 17, 20 are Jacuzzis and hot-tubs, with 73% of Jacuzzis positive for P. aeruginosa in one study. 23 A study of the home environment of 50 subjects with CF who had recently isolated P. aeruginosa for the first time showed genotypically identical environmental strains in 18% of cases, the majority of these isolates were found in the bathroom sink drain, toilet, or bath/shower drain, though due to the methodology used it is impossible to know whether these areas were the original source of the infection or whether the subjects had contracted the infection elsewhere and then had contaminated their home environment. 24 Historically, dental equipment in the form of water-containing tubing has been implicated, and this remains a concern. 25, 26 Within the healthcare setting, sink drains can frequently be contaminated with P. aeruginosa. 27 Aerosolization of the organism has been shown when taps are run into contaminated sinks, particularly during the first use of the day, presumably due to bacterial accumulation during periods of disuse. 28 Pseudomonas aeruginosa can also be cultured on the hands of healthcare workers, for as long as 180 min if coated in sputum. 27 While these issues should be resolved with appropriate hygiene methods, of much greater concern is the potential for crossinfection between subjects with CF.
A number of studies have now shown the spread of genotypically identical strains of P. aeruginosa between patients attending CF centres, particularly associated with inpatient treatment. [29] [30] [31] [32] Similar spread has been noted following residential camps for subjects with CF. 33 Although the exact mechanism of cross-infection remains uncertain, it has been shown that CF subjects with P. aeruginosa can aerosolize the organism 34, 35 and such aerosols have the potential to travel up to at least 4 m. 36 Studies in the hospital setting have suggested that segregating CF subjects to reduce the risk of crossinfection is associated with a reduction in the incidence and prevalence of chronic P. aeruginosa infection. 18, [37] [38] [39] However, even with these important hygienic measures and avoiding high-risk situations such as Jacuzzis, environmental acquisition will still occur from time to time in the majority of CF subjects. 40 As there is currently no evidence that Pseudomonas vaccination offers protection, 41 the approach for CF subjects who acquire the organism despite segrega-
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Early eradication regimen given Table 1 Definitions of Pseudomonas aeruginosa status: other definitions are used by some authors, but with modern treatments and the success of eradication regimens increasing numbers of subjects with cystic fibrosis can be classified as "free" or "intermittent" rather than "chronic," and have significantly better clinical parameters than the "chronic" group 10, 19 Definition Pseudomonas infection status
Leeds 10
Chronic: more than 50% of months when airway culture samples had been taken being P. aeruginosa culture positive a Intermittent: 50% or less of months where airway culture samples had been taken being P. aeruginosa culture positive Free: no growth of P. aeruginosa for the last 12 months, having previously been P. aeruginosa culture positive Never: never grown P. aeruginosa Copenhagen 18 Chronic: persistent presence of P. aeruginosa for at least six consecutive months, or less when combined with the presence of two or more P. aeruginosa precipitins Intermittent: culture of P. aeruginosa at least once and the presence of normal levels of precipitating antibodies against P. aeruginosa Never: never grown P. aeruginosa a The Leeds definition is based on the proportion of months when airway cultures had been taken, that had cultures positive for P. aeruginosa over the preceding 12 calendar months.
Chronic Respiratory Disease
Eradication of early Pseudomonas infection TWR Lee tion will be to detect acquisition early and institute eradication therapy.
How to detect Pseudomonas aeruginosa infection in CF subjects?
Studies of age at first isolation of P. aeruginosa are difficult to compare due to methodological differences but suggest that first acquisition occurs on average between the ages of 2 years 6 months and 5 years 8 months. 17, 38, 40, 42 In many cases, airway infection with P. aeruginosa can be detected prior to the development of any respiratory symptoms. 16, 43, 44 Early detection of P. aeruginosa therefore requires routine microbiological sampling of CF subjects as well as sampling at the onset of new respiratory symptoms.
In non-expectorating subjects, regular oropharyngeal (OP) cultures are often performed. Data in subjects who underwent paired OP culture and bronchoalveolar lavage (BAL) suggest that a negative OP culture is a reasonable predictor that the lower respiratory tract is free of P. aeruginosa (negative predictive value 85-95%). 16, 45 However, an OP culture that is positive for P. aeruginosa is less good at predicting lower respiratory tract infection (positive predictive value 44-69%). 16, 45 However, combining the results of two OP cultures 3 months apart improved the negative predictive value to 97% and positive predictive value to 83%, suggesting that in non-expectorating subjects OP cultures performed at least 3 months are a reasonable surrogate marker of lower respiratory tract infection. 16 When OP cultures are negative and symptoms or signs suggest lower respiratory tract infection, then the use of hypertonic saline to induce sputum, or BAL, may be used to determine whether P. aeruginosa infection is present. 16, [45] [46] [47] In many CF centres, the additional measurement of P. aeruginosa antibody levels is performed, although assays and cut-off levels vary widely. 48 If these are performed regularly, they may be useful in alerting the clinician to early evidence of P. aeruginosa infection before the organism is cultured from the airway. An early study of subjects in Leeds who went on to have a first positive airway culture of P. aeruginosa showed that 24 of 33 patients showed raised IgG antibodies against P. aeruginosa at or up to 2 years before initial isolation of the organism. 49 Similar results have been reported from other centres using different assays. 16, 50 The difficulty with interpreting an elevation in Pseudomonas antibodies in subjects who have negative airway cultures is that some subjects do not go on to culture P. aeruginosa. 48 The possible explanations for this include false positive antibody results, transient airway colonization that the subject clears spontaneously in between airway culture sampling, and false negative airway culture results. Because of the serious impact of chronic P. aeruginosa infection and because eradication regimens are usually welltolerated, some centres including our own will instigate eradication regimens when there is a rise in P. aeruginosa antibody titres even if airway cultures are negative, however, there is no widespread consensus with regard to this practice. 48 Once P. aeruginosa is detected, it is important that the result is acted on appropriately. Having all the CF subjects within a clinic properly categorized in terms of Pseudomonas infection status should aid the recipient of the result to identify that an eradication regimen should be instituted, if the subject is not already categorized as chronically infected. 10 What is the evidence that early eradication regimens are effective against Pseudomonas aeruginosa?
Early eradication of P. aeruginosa in subjects with CF was first described in a small case series by Littlewood, et al. 51 One of the difficulties of reviewing the literature in this area is that many different definitions of successful eradication have been used. A European consensus meeting recommended that "repeated negative respiratory cultures (at least three) within a 6-month period after the cessation of treatment in the presence of negative specific antibodies" is reasonable evidence for successful eradication. 52 This definition overcomes the danger of relying too heavily on an airway culture as soon as the eradication regimen has been completed, when an organism may still be viable at undetectable levels within the airway and ready to multiply once again.
Despite this caveat, there is now good evidence from three small randomized controlled trials (RCTs), appraised by Cochrane systematic review, that early eradication regimens against P. aeruginosa do significantly improve the clearance rate of P. aeruginosa and reduce the prevalence of chronic P. aeruginosa infection 2 years later (Table 2) . 20, [53] [54] [55] The Gibson study planned to enroll 98 subjects but was stopped early with 21 subjects enrolled http://crd.sagepub.com Eradication of early Pseudomonas infection TWR Lee aged 6 months-6 years, as interim safety analysis had shown a marked treatment effect. 55 Subjects received either 300 mg nebulized tobramycin or matching placebo for 28 days. The primary end point was eradication of P. aeruginosa from lower respiratory tract specimens. Bronchoalveolar lavage was performed on trial entry and on day 28, with OP cultures taken at entry and on days 14, 28, 42, and 56. Results are summarized in Table 2 ; it is of interest that in a small minority of subjects receiving placebo, there was apparent spontaneous clearance of P. aeruginosa in 15% of subjects at 28 days and at 56 days. 55 However, the group receiving nebulized tobramycin had a significantly better clearance rate of 100% at 1 month (P < 0.05), with 75% at 2 months. 55 Wiesemann, et al. randomized 22 subjects aged between 4 and 18 years to receive either 80 mg nebulized tobramycin twice a day for 12 months or matched placebo. Only 12 subjects completed the study, which weakens the data, but at 12 months none of the four completing placebo had cleared P. aeruginosa, whereas seven out of the eight receiving tobramycin had cleared (88%, P < 0.05). 54 Valerius, in a single-centre study, randomized 26 CF subjects aged 2-9 years to receive either ciprofloxacin orally with nebulized colomycin both for 3 weeks, and compared this with standard or no therapy, for both initial and any subsequent isolation of P. aeruginosa. The end point was time to development of chronic P. aeruginosa infection by the Copenhagen definition (see Table 1 ), a more important and relevant end point than clearance immediately after eradication is completed. 53 Two years after initial isolation of P. aeruginosa, only 14% of those receiving eradication had developed chronic P. aeruginosa infection, compared to 58% of those receiving placebo (P < 0.05).
Taken together the data from these three small RCTs strongly support eradication therapy for new acquisition of P. aeruginosa, with successful eradication in approximately 75-88% of subjects, significantly better than with placebo. The trials suggest that in a minority of CF subjects (0-15%), spontaneous clearance of P. aeruginosa may be possible with no/standard treatment.
One of the difficulties with measuring successful eradication is proving that the organism is completely eliminated from the individual, rather than just suppressed temporarily to a low level that is not detectable, particularly by cough swab. A cohort study performed by Munck, et al. 56 studied CF subjects receiving eradication therapy consisting of at least 2 weeks intravenous anti-pseudomonal antibiotics followed by at least 2 months of nebulized colistin. Initial P. aeruginosa isolates were genotyped and compared with isolates grown following eradication. All 19 subjects had a further isolation of P. aeruginosa between 3 and 25 months following initial isolation, and in 74% of subjects this was with a new strain, suggesting that the initial eradication regimen had been completely effective. The remaining 26% re-cultured the same strain suggesting that either this had simply been suppressed but not eradicated or the subjects remained in contact with a persistent environmental source of this strain of P. aeruginosa. 56 Similar results were reported by Gibson et al. 55 and Taccetti et al. 57 What agents should be used for eradication regimens for Pseudomonas aeruginosa?
Multiple different eradication regimens have been described, using different anti-pseudomonal antibiotics; varying doses and duration of therapy; and different combinations of intravenous, nebulized, or oral agents (see Table 3 ). Studies also use many different definitions for successful eradication. Such studies are therefore very difficult to compare, and there is currently insufficient evidence to determine which of these regimens is superior. Most regimens Table 3 ). Data using historical controls suggest that for ciprofloxacin and colistin, 3 months of therapy is superior to 3 weeks, but other aspects of improved care may have contributed to this improvement. 17 Early data from the ELITE study comparing 28 days versus 56 days of nebulized TOBI suggest no additional benefit in continuing this therapy beyond 28 days. 58 There are no studies that have compared ciprofloxacin and colistin with nebulized TOBI. The current EPIC study may help to determine whether the addition of oral ciprofloxacin to inhaled tobramycin is of benefit. 59 There is weak evidence from uncontrolled studies that the addition of intravenous anti-pseudomonal antibiotics may improve the efficacy of eradication, 56, 60 though it is not always demonstrated. 40 In Leeds, our retrospective audit data over 267 eradication episodes also suggest that intravenous antibiotics may offer additional benefit when combined with regimens consisting of oral and nebulized antibiotics, with success improving to 74% from 62% though this was not statistically significant. 61 Some of the possible apparent benefit of intravenous antibiotics may relate to better concordance when compared with nebulized antibiotics. 62 Thus, early eradication regimens should consist of either ciprofloxacin and colistin, probably for 3 months, or nebulized tobramycin, for at least 1 month (with or without ciprofloxacin). Intravenous antibiotics should be considered an adjunct and may offer additional benefit. Further randomized controlled studies comparing these different regimens are urgently required.
Are there any adverse effects of early eradication therapy for Pseudomonas aeruginosa?
Whenever antibiotic treatment regimens are under consideration, the potential risks of facilitating the emergence of resistant organisms or other pathogens as well as cost implications must be considered.
A recent study conducted in children receiving early eradication therapy for first acquisition of P. aeruginosa has shown that antibiotic sensitivity of the isolates is high on initial isolation and remains high on any subsequent first and second re-isolation following eradication therapy. 63 In contrast, once chronic P. aeruginosa infection is established, antibiotic resistance is common, with over 30% of isolates demonstrating resistance to ciprofloxacin in one study. 57 With respect to concerns regarding the emergence of other pathogens following eradication therapy, a small study of 47 children receiving eradication reported no significant rise in the prevalence of pathogens such as Aspergillus fumigatus, Burkholderia cepacia complex, or Stenotrophomonas maltophilia. However, the study may have been well underpowered as the prevalence of these pathogens did display a trend of increasing by 60%, 100%, and 79%, respectively, following eradication. 57 Recent data from the Australasian BAL study has shown a significant increase in isolation of A. fumigatus from children who have received eradication therapy against P. aeruginosa compared with children who had not received treatment (P = 0.002). 60 This outcome requires further evaluation in future studies, while A. fumigatus can cause both significant endobronchial infection and allergic bronchopulmonary aspergillosis (ABPA), it should be remembered that it is not generally associated with a severe decline as that seen with chronic P. aeruginosa infection. 64, 65 A pharmacoeconomic analysis comparing the cost of antibiotic treatment including initial eradication and any subsequent need for antibiotics over a 7-year period compared with age-matched controls with chronic P. aeruginosa infection over the same period showed that the antibiotic costs were 50-fold more expensive in the chronic group (105 euros compared to 5371 euros per patient per year respectively). 57 Thus, the literature suggests that early eradication regimens do not predispose to the emergence of resistant strains of P. aeruginosa, but may facilitate the emergence of other, usually less destructive pathogens such as A. fumigatus. Early eradication regimens appear cost-effective.
What are the practical aspects of delivering early eradication regimens?
Eradication regimens, often comprising 1-3 months of nebulized antibiotic twice or three times a day, with or without oral ciprofloxacin, are a considerable undertaking for CF subjects. Careful attention to the practical aspects of eradication regimen delivery is likely to improve both concordance with the therapy and effectiveness of drug delivery. 62, 66, 67 Subjects taking oral ciprofloxacin should be warned regarding photosensitivity and advised to minimize exposure to strong sunlight by keeping covered and using sun-block as appropriate. 68 Nebulized antibiotics can cause bronchospasm, and an initial supervised test dose is recommended with pre and post clinical assessments and/or lung function. [69] [70] [71] In subjects in whom bronchospasm occurs pre-dosing with an inhaled bronchodilator may allow the nebulized antibiotic to be tolerated. 69 There are a number of different nebulizers and compressors that can be used to deliver nebulized antibiotics. In general, a mouthpiece appears to offer more effective lung delivery than does a mask, but is often not tolerated in small children. 72 Disposable nebulizers such as the Ventstream ® (Respironics, Murrysville, Pennsylvania, USA) and Pari LC ® Plus (Pari GmbH, Starnberg, Germany), driven by compressors, are commonly used to deliver nebulized antibiotics. These conventional nebulizers usually take at least 7-15 min to deliver each dose and require careful washing and drying after each use to minimize the risk of bacterial contamination. 73, 74 Recently, advanced nebulizers using membrane and mesh technology have become available, such as the eFlow ® (Pari GmbH) and I-neb ® (Respironics). These devices are faster and more portable, and in the case of the I-neb ® only deliver medication during inspiration as well as record how often the medication is taken. Regular washing and drying remain important. 75 Are there any alternative approaches?
A Swedish group has reported potentially promising results using a daily mouthwash of antipseudomonal IgY in 17 subjects who had previously received antibiotic eradication for P. aeruginosa infection, with follow-up over 12 years. 76 The specific IgY is produced by immunizing hens against P. aeruginosa. When compared to matched controls at the Danish CF Centre IgY appeared safe, there was a significant increase in the time to next regrowth of P. aeruginosa, and a non-significant trend toward a reduced risk of developing chronic P. aeruginosa infection. However, there were potential confounders, most importantly several of the patients receiving IgY were on long-term azithromycin compared to none of the controls. Therefore, with no properly conducted randomized trial of this approach, there is currently insufficient evidence to support the routine use of IgY to delay the development of chronic P. aeruginosa infection.
Psychosocial considerations
Subjects with CF and their families are generally aware that P. aeruginosa is an organism that can cause significant problems. More than 40% of parents reported being "markedly stressed" that their child might acquire P. aeruginosa infection. 77
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However, knowledge regarding the organism is limited, for example, only 66% of parents were aware that successful eradication is possible following first acquisition. 77 In adolescents and adults with CF, a new acquisition of P. aeruginosa had a major and significant deleterious impact on quality of life score. 78 When a child or adult with CF has a positive airway culture for P. aeruginosa, the CF healthcare professional should be mindful of these psychosocial aspects while communicating the news and explaining the aims of the early eradication regimen. It is not unusual for the recipient of the news to be upset, and focusing on the generally positive chances of successful eradication is often helpful.
Concordance
Most studies of early eradication therapy for P. aeruginosa have not assessed concordance with therapy. Concordance with intravenous and oral medication is generally reported as good (80-95%). 79 However, concordance with long-term nebulized antibiotics in adults with CF as measured by adaptive aerosol delivery device has recently been reported as approximately 50%. 80 Barriers to adherence with nebulized antibiotics in childhood include poor time management, oppositional behavior by the child, unpleasant taste, and forgetting. 67 Good communication between CF professional and parents or subjects with CF appears to help concordance. 67 Techniques such as motivational interviewing may also be of benefit. 81 Future trials of early eradication therapy should assess concordance as this may be one of the major remaining modifiable factors that may allow further improvement in the overall efficacy of eradication regimens to be made.
Conclusions
Chronic infection with P. aeruginosa is clearly associated with greater morbidity and mortality for subjects with CF. Strict infection control measures including segregation appear to reduce but not eliminate the risk of initial acquisition of the organism.
There is now good evidence that early eradication regimens consisting of anti-pseudomonal antibiotics are effective in clearing P. aeruginosa and delaying the development of chronic infection in the majority of subjects. Ensuring that such regimens are widely adopted is therefore of considerable importance to improve outcomes for subjects with CF. The most effective antibiotic regimen and the effects of new nebulizer technologies and methods to improve concordance remain to be determined.
